Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 43598-352

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 43598-352). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

FDA Label Image

Carton2 (Carton2)

FDA Label Image

Carton3 (Carton3)

This text is not readable and the description cannot be generated.*

FDA Label Image

Carton4 (Carton4)

FDA Label Image

Container1 (Container1)

FDA Label Image

Container2 (Container2)

FDA Label Image

Container3 (Container3)

FDA Label Image

Container4 (Container4)

FDA Label Image

Figure1 (Figure1)

This text provides information on the impact of certain drugs on the pharmacokinetics of Lurasidone. The drugs are categorized based on their ability to inhibit or induce CYP3A4, a liver enzyme that metabolizes many medications. The text reports the fold change and 90% CI for Lurasidone's Cmax and AUC when co-administered with the interacting drug. Ketoconazole, a strong CYP3A4 inhibitor, increased Lurasidone's Cmax and AUC. Diltiazem, a moderate CYP3A4 inhibitor, increased Lurasidone's Cmax and AUC to a lesser extent. Rifampin, a strong CYP3A4 inducer, decreased Lurasidone's Cmax and AUC. Finally, Lithium did not change Lurasidone's Cmax or AUC.*

FDA Label Image

Figure2 (Figure2)

This appears to be a table containing information about the fold change and 90% confidence interval for various drugs and their substrates. The top row contains column headers indicating the drugs or substrates being studied, and the units being measured (e.g. mg, Cmax). The row below the headers appears to show the fold change and confidence intervals for each substrate when interacting with the given drug. The last row shows the change relative to the interactive drug alone. However, more context is needed to fully understand what this table is analyzing.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.